drugset
drugset / Trial / NCT00053222

Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine

NCT00053222 ↗

Phase 2 Completed 13 enrolled University of Chicago National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have locally advanced or metastatic pancreatic cancer that has not responded to gemcitabine.

Timeline

Start
2003-02
Primary completion
2005-01
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject arsenic trioxide Small molecule 0.3 mg/kg Intravenous

Indications

malignant pancreatic neoplasm